MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/cncr.70102

Медицинская библиотека · Cancer · 2025

Validation of the Functional Assessment of Cancer Therapy - Immune Checkpoint Modulator 17-Item Symptom Index (FACT-ICM-17) to facilitate implementation in research and clinical care.

Gudenkauf Lisa M, Tometich Danielle B, Hoogland Aasha I, Li Xiaoyin, Kirtane Kedar, Small Brent J, Barata Anna, Gonzalez Brian D, Jacobs K D, Chung Christine H, Shafique Michael R, Gray Jhanelle, Khushalani Nikhil I, Postow Michael A, Cella David, Webster Kimberly A, Dicker Adam P, Jim Heather S L

СтатьяВалидационное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Immune checkpoint modulators (ICMs) have revolutionized cancer treatment but have unique immune-related adverse events (irAEs). The aim of this study was to develop and validate a brief measure of the most common, distressing, and diagnostically useful symptomatic irAEs.

METHODS

Items were generated to assess symptomatic irAEs through a multistep process of (1) literature review and iterative expert input and (2) qualitative interviews of patients, caregivers, and clinicians regarding ICM-related irAEs and quality of life (QOL) impacts. An initial item set was administered across five longitudinal or cross-sectional studies. The final item set was selected using a Delphi method; validity, reliability, minimally important differences (MIDs), and sensitivity to change were evaluated.

RESULTS

Qualitative interviews with 14 patients, seven caregivers, and six clinicians informed an initial set of 46 symptomatic irAEs, which was administered to patients (N = 503, 52% female, mean age = 64) treated with ICMs for non-small cell lung cancer (n = 342), head and neck cancer (n = 72), renal cell carcinoma (n = 43), or melanoma (n = 46). A final item set was selected and mapped to FACIT library items. This produced the 17-item FACT-ICM Symptom Index, which showed reliability (α = 0.86), construct validity (comparative fit index = 0.93), convergent validity with validated measures of physical QOL (r = 0.69-0.73), discriminant validity with emotional and social QOL (r = 0.03-0.65), and criterion validity (i.e., better performance status was associated with fewer concerns). Response option anchors adequately captured MIDs and were sensitive to change.

CONCLUSIONS

This brief 17-item FACT-ICM Symptom Index demonstrates initial construct, convergent, and divergent validity, reliability, MID, and sensitivity to change and is ready for use in research and clinical care.

Для цитирования: Gudenkauf Lisa M, Tometich Danielle B, Hoogland Aasha I, Li Xiaoyin, Kirtane Kedar, Small Brent J, Barata Anna, Gonzalez Brian D, Jacobs K D, Chung Christine H, Shafique Michael R, Gray Jhanelle, Khushalani Nikhil I, Postow Michael A, Cella David, Webster Kimberly A, Dicker Adam P, Jim Heather S L. Validation of the Functional Assessment of Cancer Therapy - Immune Checkpoint Modulator 17-Item Symptom Index (FACT-ICM-17) to facilitate implementation in research and clinical care.. Cancer. 2025. DOI: 10.1002/cncr.70102.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.